AC
MDNA

Annandale Capital’s Medicenna Therapeutics Corp. Common Shares MDNA Stock Holding History

Annandale Capital’s Portfolio MDNA Stock Details MDNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-40,000
Closed -$19K – 150
2023
Q2 		$19K Hold
40,000
– – 0.01% 137
2023
Q1 		$26K Hold
40,000
– – 0.01% 133
2022
Q4 		$19K Hold
40,000
– – 0.01% 134
2022
Q3 		$33K Buy
+40,000
New +$45.2K 0.01% 133

Other funds holding MDNA

ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
LBA
Letko, Brosseau & Associates Montreal, Quebec, Canada $6.2B AUM 38.92% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
MCWS
McKinley Carter Wealth Services Wheeling, West Virginia $1.94B AUM 20.7% 1-Year Est. Return

Annandale Capital's MDNA Position: Q3 2023 in Review

Annandale Capital sold out of Medicenna Therapeutics Corp. Common Shares (MDNA) in Q3 2023, closing a stake of 40,000 shares — an estimated $19K sold.

Annandale Capital first reported a position in MDNA in Q3 2022 and held it in 4 quarters. The position peaked at $33K in Q3 2022. 25 funds tracked by Wall St. Rank hold MDNA as of Q3 2023.

  • Annandale Capital reported no remaining Medicenna Therapeutics Corp. Common Shares position as of Q3 2023 after selling out during the quarter.
  • Annandale Capital sold 40,000 Medicenna Therapeutics Corp. Common Shares shares in Q3 2023, an estimated $19K.
  • Annandale Capital first reported a position in Medicenna Therapeutics Corp. Common Shares in Q3 2022 and held it in 4 quarters.
  • Annandale Capital's Medicenna Therapeutics Corp. Common Shares position peaked at $33K in Q3 2022.
  • 25 funds tracked by Wall St. Rank held Medicenna Therapeutics Corp. Common Shares as of Q3 2023.

Based on Annandale Capital's 13F filing for Q3 2023, filed 15 Nov 2023.